Chemosensitivity linked to p73 function

被引:369
作者
Irwin, MS
Kondo, K
Marin, MC
Cheng, LS
Hahn, WC
Kaelin, WG
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
[3] Howard Hughes Med Inst, Coconut Grove, FL 33133 USA
[4] Univ Toronto, Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S1535-6108(03)00078-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Most chemotherapeutic agents induce DNA damage, leading to p53 accumulation and apoptosis. The factors that determine chemosensitivity in p53-defective tumor cells are poorly understood. We found that the p53 family member p73 is induced by a wide variety of chemotherapeutic drugs. Blocking p73 function with a dominant-negative mutant, siRNA, or homologous recombination led to chemoresistance of human tumor cells and engineered transformed cells, irrespective of p53 status. Mutant p53 can inactivate p73 and downregulation of mutant p53 enhanced chemosensitivity. These findings indicate that p73 is a determinant of chemotherapeutic efficacy in humans.
引用
收藏
页码:403 / 410
页数:8
相关论文
共 41 条
  • [1] Agami R, 1999, NATURE, V399, P809
  • [2] Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73
    Bensaad, K
    Le Bras, M
    Unsal, K
    Strano, S
    Blandino, G
    Tominaga, O
    Rouillard, D
    Soussi, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (12) : 10546 - 10555
  • [3] p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis
    Bergamaschi, D
    Gasco, M
    Hiller, L
    Sullivan, A
    Syed, N
    Trigiante, G
    Yulug, I
    Merlano, M
    Numico, G
    Comino, A
    Attard, M
    Reelfs, O
    Gusterson, B
    Bell, AK
    Heath, V
    Tavassoli, M
    Farrell, PJ
    Smith, P
    Lu, X
    Crook, T
    [J]. CANCER CELL, 2003, 3 (04) : 387 - 402
  • [4] Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
    Blandino, G
    Levine, AJ
    Oren, M
    [J]. ONCOGENE, 1999, 18 (02) : 477 - 485
  • [5] Brooks LA, 2000, CANCER RES, V60, P6875
  • [6] Brown JM, 1999, CANCER RES, V59, P1391
  • [7] Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
    Bykov, VJN
    Issaeva, N
    Shilov, A
    Hultcrantz, M
    Pugacheva, E
    Chumakov, P
    Bergman, J
    Wiman, KG
    Selivanova, G
    [J]. NATURE MEDICINE, 2002, 8 (03) : 282 - 288
  • [8] Molecular alterations of p73 in human esophageal squamous cell carcinomas:: loss of heterozygosity occurs frequently;: loss of imprinting and elevation of p73 expression may be related to defective p53
    Cai, YYC
    Yang, GY
    Nie, Y
    Wang, LD
    Zhao, X
    Song, YL
    Seril, DN
    Liao, J
    Xing, EP
    Yang, CS
    [J]. CARCINOGENESIS, 2000, 21 (04) : 683 - 689
  • [9] p73 is transcriptionally regulated by DNA damage, p53, and p73
    Chen, XB
    Zheng, YM
    Zhu, JH
    Jiang, JY
    Wang, J
    [J]. ONCOGENE, 2001, 20 (06) : 769 - 774
  • [10] DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes
    Costanzo, A
    Merlo, P
    Pediconi, N
    Fulco, M
    Sartorelli, V
    Cole, PA
    Fontemaggi, G
    Fanciulli, M
    Schiltz, L
    Blandino, G
    Balsano, C
    Levrero, M
    [J]. MOLECULAR CELL, 2002, 9 (01) : 175 - 186